This study presents the results of evaluating the efficacy and safety of the next-generation nootropic Pantogam Active (D-, L-hopantenic acid) in the comprehensive therapy of 80 patients with arterial hypertension accompanied by cognitive and anxiety disorders. It was found that administration of the drug at a dose of 600–1200 mg/day for 28 days provided a significant improvement (p < 0.05) in cognitive functions, as evidenced by increased scores on the MoCA and MMSE scales, as well as enhanced attention span and memory capacity.

The drug demonstrated pronounced anxiolytic effects, reducing anxiety levels on the HADS scale by 32%, exceeding the outcomes of standard antihypertensive therapy. Pantogam Active showed a high safety profile and good tolerability, supporting its recommendation as an effective bimodal agent for neuroprotection and correction of psycho-emotional status in patients with chronic cerebrovascular diseases.

Pantogam Active, hopantenic acid, arterial hypertension

Smulevich A.B., Volel B.A., et al. Pantogam Active (D-, L-hopantenic acid) in the therapy of cognitive and anxiety disorders in patients with arterial hypertension. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2015; 115(12): 40–49.

Voronina T.A., Litvinova S.A. Pharmacological effects and clinical use of hopantenic acid preparations. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2017; 117(8): 132–139.

Ostroumova O.D. Possibilities of using D-, L-hopantenic acid in the comprehensive therapy of cognitive and anxiety disorders. Medical Council. 2018.